REGENXBIO INC (RGNX)
US75901B1070 - Common Stock
RGNX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. The financial health of RGNX is average, but there are quite some concerns on its profitability. RGNX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RGNX had negative earnings in the past year.
RGNX had a negative operating cash flow in the past year.
RGNX had negative earnings in 4 of the past 5 years.
In the past 5 years RGNX reported 4 times negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -46.00%, RGNX perfoms like the industry average, outperforming 51.16% of the companies in the same industry.
The Return On Equity of RGNX (-79.23%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46% | ||
| ROE | -79.23% | ||
| ROIC | N/A |
ROA(3y)-22.69%
ROA(5y)-20.56%
ROE(3y)-40.7%
ROE(5y)-34.52%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RGNX has a Gross Margin of 54.36%. This is in the better half of the industry: RGNX outperforms 78.79% of its industry peers.
RGNX's Gross Margin has declined in the last couple of years.
RGNX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.58%
GM growth 5Y-9.28%
2. Health
2.1 Basic Checks
RGNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RGNX has been increased compared to 1 year ago.
RGNX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -1.96, we must say that RGNX is in the distress zone and has some risk of bankruptcy.
RGNX has a Altman-Z score of -1.96. This is comparable to the rest of the industry: RGNX outperforms 53.30% of its industry peers.
There is no outstanding debt for RGNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.96 |
ROIC/WACCN/A
WACC10.41%
2.3 Liquidity
RGNX has a Current Ratio of 3.05. This indicates that RGNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.05, RGNX is doing worse than 64.53% of the companies in the same industry.
A Quick Ratio of 3.05 indicates that RGNX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.05, RGNX is doing worse than 62.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.05 | ||
| Quick Ratio | 3.05 |
3. Growth
3.1 Past
RGNX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.72%, which is quite good.
The Revenue for RGNX has decreased by -15.08% in the past year. This is quite bad
Measured over the past years, RGNX shows a very negative growth in Revenue. The Revenue has been decreasing by -16.21% on average per year.
EPS 1Y (TTM)16.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.02%
Revenue 1Y (TTM)-15.08%
Revenue growth 3Y-16.43%
Revenue growth 5Y-16.21%
Sales Q2Q%-16.31%
3.2 Future
The Earnings Per Share is expected to grow by 16.53% on average over the next years. This is quite good.
RGNX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 41.53% yearly.
EPS Next Y20.14%
EPS Next 2Y34.89%
EPS Next 3Y11.45%
EPS Next 5Y16.53%
Revenue Next Year-6.62%
Revenue Next 2Y71.44%
Revenue Next 3Y35.93%
Revenue Next 5Y41.53%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for RGNX. In the last year negative earnings were reported.
Also next year RGNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.89%
EPS Next 3Y11.45%
5. Dividend
5.1 Amount
RGNX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REGENXBIO INC
NASDAQ:RGNX (11/15/2024, 8:00:01 PM)
Premarket: 11.5 +1.87 (+19.42%)9.63
-1.51 (-13.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap477.17M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -46% | ||
| ROE | -79.23% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 54.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.16
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.05 | ||
| Quick Ratio | 3.05 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)16.72%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y20.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-15.08%
Revenue growth 3Y-16.43%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y